Your browser doesn't support javascript.
loading
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.
Ekman, Simon; Griesinger, Frank; Baas, Paul; Chao, David; Chouaid, Christos; O'Donnell, John C; Penrod, John R; Daumont, Melinda; Lacoin, Laure; McKenney, Alexia; Khovratovich, Masha; Munro, Robin Ej; Durand-Zaleski, Isabelle; Johnsen, Søren Paaske.
Afiliación
  • Ekman S; Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
  • Griesinger F; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Baas P; Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany.
  • Chao D; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Chouaid C; Department of Oncology, Royal Free Hospital, London, UK.
  • O'Donnell JC; Pneumology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
  • Penrod JR; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Daumont M; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Lacoin L; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
  • McKenney A; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
  • Khovratovich M; Real-World & Analytics Solutions, IQVIA, London, UK.
  • Munro RE; Real-World & Analytics Solutions, IQVIA, London, UK.
  • Durand-Zaleski I; Real-World & Analytics Solutions, IQVIA, London, UK.
  • Johnsen SP; URC Eco IdF, Unité de Recherche Clinique en Économie de la Santé d'Ile de France, AP-HP Paris, Paris, France.
Future Oncol ; 15(14): 1551-1563, 2019 May.
Article en En | MEDLINE | ID: mdl-30852916
Aim: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer management. Materials & methods: Real-world data source selection for I-O Optimise followed a structured approach focused on population coverage, key variable capture, continuous/consistent data availability, record duration and data latency, and database expertise. Results: As of 31 October 2018, seven real-world data sources were included in I-O Optimise, providing data on characteristics, treatment patterns and clinical outcomes from more than 45,000 patients/year with non-small-cell lung cancer, small-cell lung cancer and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK. Conclusion: The ongoing I-O Optimise initiative has the potential to provide a broad, robust and dynamic research platform to continually address numerous research objectives in the lung cancer arena.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Investigación / Neoplasias Torácicas / Informática Médica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Future Oncol Año: 2019 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Investigación / Neoplasias Torácicas / Informática Médica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Future Oncol Año: 2019 Tipo del documento: Article País de afiliación: Suecia